# Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension

> **NCT02322450** · PHASE2 · COMPLETED · sponsor: **Quantum Genomics SA** · enrollment: 34 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** QGC001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02322450
- **Lead sponsor:** Quantum Genomics SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322450, "Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02322450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*